Artículo
Cannabidiol in children with treatment-resistant epilepsy with myoclonic-atonic seizures
Caraballo, Roberto Horacio
; Reyes Valenzuela, Gabriela; Fortini, Sebastian; Espeche, Alberto; Gamboni, Beatriz; Silva, Walter
; Semprino, Marcos; Fasulo, Lorena; Chacón, Santiago; Gallo, Adolfo; Galicchio, Santiago; Cachia, Pedro
![Icon](/themes/CONICETDigital/images/conicet.png)
![Icon](/themes/CONICETDigital/images/conicet.png)
Fecha de publicación:
05/2023
Editorial:
Elsevier
Revista:
Epilepsy and Behavior
e-ISSN:
1525-5069
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
Purpose: This multicenter study aimed to evaluate the efficacy and tolerability of add-on cannabidiol (CBD) in treatment-resistant patients with epilepsy with myoclonic-atonic seizures (EMAtS) (n = 22) and Sturge Weber syndrome (SWS) with myoclonic-atonic seizures (n = 4). Methods: Patients who met the diagnostic criteria of treatment-resistant EMAtS or SWS with myoclonic-atonic seizures were included. Cannabidiol was added in doses ranging from 8 to 40 mg/kg/day. Efficacy was assessed by comparing seizure frequency before and after initiating CBD therapy. Neurologic examinations, brain magnetic resonance imaging, repeated prolonged electroencephalography (EEG) and/or video-EEG recordings, and neurometabolic studies were performed in all patients, and genetic investigations in 15. Results: After a mean follow-up of 19 months, 15/26 patients (57.7%) who received add-on CBD had a >50% seizure decrease; three (11.5%) became seizure-free. The remaining 11 patients (42.3%) had a 25–50% seizure reduction. Drop attacks, including myoclonic-atonic seizures and generalized tonic-clonic seizures, as well as atypical absences and nonconvulsive status epilepticus responded well to CBD. In SWS patients, focal motor seizures without consciousness impairment and focal non-motor seizures with consciousness impairment were recognized in two each; in three a 30% reduction of focal seizures was observed. Side effects were mild and did not lead to CBD discontinuation. Conclusion: This study evaluating the use of add-on CBD in children with EMAtS or SWS with myoclonic-atonic seizures found that 15/26 (57.7%) had a >50% seizure reduction with good tolerability; three (11.5%) became seizure-free.
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(SEDE CENTRAL)
Articulos de SEDE CENTRAL
Articulos de SEDE CENTRAL
Citación
Caraballo, Roberto Horacio; Reyes Valenzuela, Gabriela; Fortini, Sebastian; Espeche, Alberto; Gamboni, Beatriz; et al.; Cannabidiol in children with treatment-resistant epilepsy with myoclonic-atonic seizures; Elsevier; Epilepsy and Behavior; 143; 5-2023; 1-8
Compartir
Altmétricas